The U.S. FDA Approved NEXT BIOMEDICAL's Nexpowder For Lower GI Bleeding

Next Biomedical, a South Korean medical solutions company, announced that its product, Nexpowder, has received approval from the U.S. Food and Drug Administration (FDA). Nexpowder is designed to treat lower gastrointestinal (GI) bleeding.

This approval expands the application of Nexpowder, as it was previously limited to upper GI tract conditions and now will include the lower GI tract. Nexpowder is a powdered treatment developed for endoscopic procedures to control bleeding in the gastrointestinal tract. It is designed to provide quick and adequate haemostasis, especially in emergencies.

Lee Don-haeng, CEO of Next Biomedicine, said, “With this indication expansion, Nexpowder can now be effectively utilised in various areas of gastrointestinal bleeding prevention. We aim to further accelerate sales growth by establishing Nexpowder as a trusted solution in the global market.”

Next BIOMEDICAL is actively exploring licensing agreements for Nexpowder in regions such as South America, the Middle East, and Japan, aiming to broaden its global reach.